{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:43:14Z","timestamp":1789188194725,"version":"build-2803163510"},"reference-count":206,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T00:00:00Z","timestamp":1664841600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01NS117209"],"award-info":[{"award-number":["U01NS117209"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01NS117278"],"award-info":[{"award-number":["U01NS117278"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-16-1-0660"],"award-info":[{"award-number":["W81XWH-16-1-0660"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-21-1-0305"],"award-info":[{"award-number":["W81XWH-21-1-0305"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-21-1-0311"],"award-info":[{"award-number":["W81XWH-21-1-0311"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-21-1-0314"],"award-info":[{"award-number":["W81XWH-21-1-0314"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.expneurol.2022.114237","type":"journal-article","created":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T01:59:53Z","timestamp":1664848793000},"page":"114237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"special_numbering":"C","title":["Therapeutic and clinical foundations of cannabidiol therapy for difficult-to-treat seizures in children and adults with refractory epilepsies"],"prefix":"10.1016","volume":"359","author":[{"given":"Doodipala Samba","family":"Reddy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.expneurol.2022.114237_bb0005","first-page":"14","article-title":"Anticonvulsant effect of cannabidiol","volume":"69","author":"Ames","year":"1986","journal-title":"S. Afr. Med. J."},{"issue":"11","key":"10.1016\/j.expneurol.2022.114237_bb0010","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1111\/epi.16355","article-title":"Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions","volume":"60","author":"Anderson","year":"2019","journal-title":"Epilepsia."},{"issue":"24","key":"10.1016\/j.expneurol.2022.114237_bb0015","doi-asserted-by":"crossref","first-page":"4826","DOI":"10.1111\/bph.15661","article-title":"Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy","volume":"178","author":"Anderson","year":"2021","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.expneurol.2022.114237_bb0020","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1177\/0883073809348355","article-title":"Increased risk of death among children with Lennox-Gastaut syndrome and infantile spasms","volume":"25","author":"Autry","year":"2010","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.expneurol.2022.114237_bb0025","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.phrs.2017.02.022","article-title":"The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABAA receptors","volume":"119","author":"Bakas","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.expneurol.2022.114237_bb0030","series-title":"Non-Seizure Related Outcomes with Real-World Use of Cannabidiol (CBD) in Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS): BECOME, a Caregiver Survey","author":"Berg","year":"2021"},{"issue":"8","key":"10.1016\/j.expneurol.2022.114237_bb0035","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/mp.2008.119","article-title":"The mood improving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling","volume":"14","author":"Bessa","year":"2009","journal-title":"Mol. Psychiatry"},{"issue":"6","key":"10.1016\/j.expneurol.2022.114237_bib1012","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/epi.16542","article-title":"Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials","volume":"61","author":"Bialer","year":"2020","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.expneurol.2022.114237_bb0040","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/WCO.0000000000000660","article-title":"Cannabinoid therapy in epilepsy","volume":"32","author":"Billakota","year":"2019","journal-title":"Curr. Opin. Neurol."},{"issue":"8","key":"10.1016\/j.expneurol.2022.114237_bb0045","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/epi.16093","article-title":"Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy","volume":"60","author":"Birnbaum","year":"2019","journal-title":"Epilepsia."},{"key":"10.1016\/j.expneurol.2022.114237_bb0050","first-page":"1911","article-title":"Cannabinoids: is there a potential treatment role in epilepsy? Expert Opin","volume":"16","author":"Blair","year":"2015","journal-title":"Pharmacother."},{"issue":"Suppl. 4","key":"10.1016\/j.expneurol.2022.114237_bb0055","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/epi.12567","article-title":"Lennox-Gastaut syndrome: a consensus approach to differential diagnosis","volume":"55","author":"Bourgeois","year":"2014","journal-title":"Epilepsia."},{"key":"10.1016\/j.expneurol.2022.114237_bb0060","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.jpsychires.2012.08.012","article-title":"Cannabidiol block long-lasting behavioral consequences of predator threat stress: possible involvement of 5HT1A receptors","volume":"46","author":"Campos","year":"2012","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.expneurol.2022.114237_bb0065","first-page":"3364","article-title":"Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders","volume":"367","author":"Campos","year":"2012","journal-title":"Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci."},{"key":"10.1016\/j.expneurol.2022.114237_bb0070","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3389\/fphar.2017.00269","article-title":"Plastic and neuroprotective mechanisms involved in the therapeutic effects of cannabidiol in psychiatric disorders","volume":"8","author":"Campos","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.expneurol.2022.114237_bb0075","first-page":"048","article-title":"An evaluation of effectivenss of cannabidiol as an antiepileptic drug for children with intractable generalized epilepsy","volume":"1","author":"Carney","year":"2017","journal-title":"AES Abstract"},{"issue":"2","key":"10.1016\/j.expneurol.2022.114237_bb0080","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.nbd.2009.10.023","article-title":"The neuroprotective effect of cannabidiol in an in vitro model of newborn hyper-ischemic brain damage in mice is mediated by CB2 and adenosine receptors","volume":"37","author":"Castillo","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2022.114237_bb0085","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/j.1528-1167.2012.03495.x","article-title":"Successful use of fenfluramine as an add-on treatment for Dravet syndrome","volume":"53","author":"Ceulemans","year":"2012","journal-title":"Epilepsia."},{"key":"10.1016\/j.expneurol.2022.114237_bb0090","series-title":"An assessment of the anticonvulsant efficacy of cannabinoids in an invitro model of mitochondrial epilepsy","author":"Chan","year":"2018"},{"issue":"3","key":"10.1016\/j.expneurol.2022.114237_bb0095","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","article-title":"Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study","volume":"75","author":"Chen","year":"2018","journal-title":"JAMA Neurol."},{"issue":"11","key":"10.1016\/j.expneurol.2022.114237_bb0100","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/s41386-020-0667-2","article-title":"Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials","volume":"45","author":"Chesney","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.expneurol.2022.114237_bb0105","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.seizure.2021.05.025","article-title":"Prevalence, healthcare resource utilization and mortality of Lennox-Gastaut syndrome: retrospective linkage cohort study","volume":"91","author":"Chin","year":"2021","journal-title":"Seizure"},{"key":"10.1016\/j.expneurol.2022.114237_bb0110","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1124\/pr.119.017392","article-title":"Sex differences in the epilepsies and associated comorbidities: implications for use and development of pharmacotherapies","volume":"72","author":"Christine","year":"2020","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.expneurol.2022.114237_bb0115","first-page":"294","article-title":"Long-term safety of pharmaceutical cannabidiol oral solution as adjunctive treatment for pediatric patients with treatment-resistant epilepsy","volume":"3","author":"Cilio","year":"2018","journal-title":"American Epilepsy Society Abstract"},{"issue":"6","key":"10.1016\/j.expneurol.2022.114237_bb0120","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.bbadis.2017.02.003","article-title":"Novel therapeutic approaches for disease-modification of epileptogenesis for curing epilepsy","volume":"1863","author":"Clossen","year":"2017","journal-title":"Biochim. Biophys. Acta Mol. basis Dis."},{"key":"10.1016\/j.expneurol.2022.114237_bb0125","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jama.1975.03260160054015","article-title":"Anticonvulsant nature of marihuana smoking","volume":"234","author":"Consroe","year":"1975","journal-title":"JAMA."},{"issue":"4","key":"10.1016\/j.expneurol.2022.114237_bib1005","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/0091-3057(82)90418-X","article-title":"Effects of marihuana cannabinoids on seizure activity in cobalt-epileptic rats","volume":"16","author":"Colasanti","year":"1982","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.expneurol.2022.114237_bb0130","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0014-2999(82)90264-3","article-title":"Effects of cannabidiol on behavioral seizures caused by convulsants drugs or current in mice","volume":"83","author":"Consroe","year":"1982","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2022.114237_bb0135","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMra055323","article-title":"The tuberous sclerosis complex","volume":"355","author":"Crino","year":"2006","journal-title":"NEJM"},{"issue":"1","key":"10.1016\/j.expneurol.2022.114237_bb0140","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/0269881110379283","article-title":"Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report","volume":"25","author":"Crippa","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.expneurol.2022.114237_bb0145","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.3389\/fimmu.2018.02009","article-title":"Translational investigation of the therapeutic potential of cannabidiol: toward a new age","volume":"9","author":"Crippa","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.expneurol.2022.114237_bb0150","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000137430","article-title":"Chronic administration of cannabidiol to healthy volunteers and epileptic patients","volume":"21","author":"Cunha","year":"1980","journal-title":"Pharmacol."},{"issue":"5","key":"10.1016\/j.expneurol.2022.114237_bb0155","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ejpn.2018.05.006","article-title":"Management of epilepsy associated with tuberous sclerosis complex: updated clinical recommendations","volume":"22","author":"Curatolo","year":"2018","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"1","key":"10.1016\/j.expneurol.2022.114237_bb0160","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s12035-013-8514-7","article-title":"Cannabidiol normalizes caspase 3, synaptophysin, and mitochondrial fission protein DNM1L expression levels in rats with brain iron overload: implications for neuroprotection","volume":"49","author":"Da Silva","year":"2014","journal-title":"Mol. Neurobiol."},{"issue":"3","key":"10.1016\/j.expneurol.2022.114237_bb0170","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s00213-011-2415-0","volume":"219","author":"Deianna","year":"2012","journal-title":"Psychopharmacology."},{"issue":"1","key":"10.1016\/j.expneurol.2022.114237_bib1003","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.neulet.2006.09.046","article-title":"Cannabinoid CB1 receptor antagonists cause status epilepticus-like activity in the hippocampal neuronal culture model of acquired epilepsy","volume":"411","author":"Deshpande","year":"2007","journal-title":"Neurosci. Lett."},{"issue":"21","key":"10.1016\/j.expneurol.2022.114237_bb0175","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of Cannabidiol for drug-resistant seizures in the Dravet Syndrome","volume":"376","author":"Devinksy","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.expneurol.2022.114237_bb0180","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/epi.12631","article-title":"Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders","volume":"55","author":"Devinsky","year":"2014","journal-title":"Epilepsia."},{"key":"10.1016\/j.expneurol.2022.114237_bb0185","series-title":"Efficacy and safety of Epidiolex (cannabidiol) in children and young adults with treatment-resistant epilepsy: Initial data from an expanded access program. AES Meeting (Chicago, IL). AES Abstract #","author":"Devinsky","year":"2014"},{"key":"10.1016\/j.expneurol.2022.114237_bb0190","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S1474-4422(15)00379-8","article-title":"Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial","volume":"15","author":"Devinsky","year":"2016","journal-title":"Lancet Neurol."},{"issue":"20","key":"10.1016\/j.expneurol.2022.114237_bb0195","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","article-title":"Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome","volume":"378","author":"Devinsky","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.expneurol.2022.114237_bb0200","doi-asserted-by":"crossref","first-page":"e1204","DOI":"10.1212\/WNL.0000000000005254","article-title":"Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome","volume":"90","author":"Devinsky","year":"2018","journal-title":"Neurology."},{"issue":"2","key":"10.1016\/j.expneurol.2022.114237_bb0205","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/epi.14628","article-title":"Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial","volume":"60","author":"Devinsky","year":"2019","journal-title":"Epilepsia."},{"issue":"6","key":"10.1016\/j.expneurol.2022.114237_bib1009","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/ane.13305","article-title":"Cannabidiol efficacy independent of clobazam: Meta-analysis of four randomized controlled trials","volume":"142","author":"Devinsky","year":"2020","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.expneurol.2022.114237_bb0210","series-title":"Seizure Related Outcomes with Real-World Use of Cannabidiol (CBD) in Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS): BECOME, a Caregiver Survey","author":"Dixon-Salazar","year":"2021"},{"key":"10.1016\/j.expneurol.2022.114237_bb0215","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3389\/fphar.2017.00131","article-title":"Protective effects of cannabidiol against seizures and neuronal death in a rat model of mesial temporal lobe epilepsy","volume":"8","author":"Do Val-da Silva","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.expneurol.2022.114237_bb0220","series-title":"Alterations in sleep architecture with CBD use. Abstract 2.269, American Epilepsy Society, New Orleans, LA","author":"Drake","year":"2018"},{"key":"10.1016\/j.expneurol.2022.114237_bb0225","first-page":"71","article-title":"Severe myoclonic epilepsy in infancy: Dravet syndrome","volume":"95","author":"Dravet","year":"2005","journal-title":"Adv. Neurol."},{"key":"10.1016\/j.expneurol.2022.114237_bb0230","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.pediatrneurol.2019.11.017","article-title":"Cannabidiol elevates mechanistic target of rapamycin inhibitor levels in patients with tuberous sclerosis complex","volume":"105","author":"Ebrahimi-Fakhari","year":"2020","journal-title":"Pediatr. Neurol."},{"issue":"1","key":"10.1016\/j.expneurol.2022.114237_bb0235","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/epi.14608","article-title":"Cannabis-based products for pediatric epilepsy: a systematic review","volume":"60","author":"Elliott","year":"2019","journal-title":"Epilepsia."},{"key":"10.1016\/j.expneurol.2022.114237_bb0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.121.000994","article-title":"Therapeutic Basis of generic substitution of Antiseizure Medications","volume":"381","author":"Elmer","year":"2022","journal-title":"J. Pharmacol. Exp. Therap."},{"key":"10.1016\/j.expneurol.2022.114237_bb0245","series-title":"Handbook of Cannabis","first-page":"3","article-title":"Constituents of Cannabis sativa","author":"ElSohly","year":"2014"},{"issue":"12","key":"10.1016\/j.expneurol.2022.114237_bb0250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028668","article-title":"Cannabidiol reduces A\u03b2-induced neuroinflammation and promotes hippocampal neurogenesis through PPAR\u03b3 involvement","volume":"6","author":"Esposito","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.expneurol.2022.114237_bb0255","series-title":"Drug Approval Package: Epidiolex (Cannabidiol)","author":"FDA","year":"2018"},{"key":"10.1016\/j.expneurol.2022.114237_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108442","article-title":"Cannabidiol in the treatment of epilepsy: current evidence and perspectives for further research","volume":"185","author":"Franco","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.expneurol.2022.114237_bb0265","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.seizure.2021.04.008","article-title":"Cannabidiol modifies the seizure expression and effects of antiseizure drugs in a rat model of recurrent severe seizures","volume":"90","author":"Fr\u00edas-Soria","year":"2021","journal-title":"Seizure"},{"key":"10.1016\/j.expneurol.2022.114237_bb0270","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1056\/NEJMra1407304","article-title":"Cannabinoids in the treatment of epilepsy","volume":"373","author":"Friedman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.expneurol.2022.114237_bb0275","series-title":"The effect of Epidiolex (cannabidiol) on serum levels of concomitant anti-epileptic drugs in children and young adults with treatment-resistant epilepsy in an expanded access program","author":"Friedman","year":"2014"},{"issue":"Suppl. 1","key":"10.1016\/j.expneurol.2022.114237_bb0280","doi-asserted-by":"crossref","first-page":"S223","DOI":"10.1016\/j.eplepsyres.2006.01.019","article-title":"Clinical spectrum of mutations in SCN1A gene: severe myoclonic epilepsy in infancy and related epilepsies","volume":"70","author":"Fujiwara","year":"2006","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.expneurol.2022.114237_bb0285","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1432-1033.1995.tb20780.x","article-title":"Expression of central and peripheral cannabinoid recepors in human immune tissues and leukocyte subpopulations","volume":"232","author":"Galiegue","year":"1995","journal-title":"Eur. J. Biochem."},{"issue":"2","key":"10.1016\/j.expneurol.2022.114237_bb0290","article-title":"Pharmacology of cannabinoids in the treatment of epilepsy","volume":"15","author":"Gaston","year":"2019","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.expneurol.2022.114237_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.107862","article-title":"Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy","volume":"117","author":"Gaston","year":"2021","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.expneurol.2022.114237_bb0300","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.seizure.2016.10.014","article-title":"From genotype to phenotype in Dravet disease","volume":"44","author":"Gataullina","year":"2017","journal-title":"Seizure."},{"key":"10.1016\/j.expneurol.2022.114237_bb0305","series-title":"American Epilepsy Society annual meeting, Seattle, WA. Abst. 3.330","article-title":"Whole cannabis extract of high concentration cannabidiol may calm seizures in highly refractory pediatric epilepsies","author":"Gedde","year":"2013"},{"key":"10.1016\/j.expneurol.2022.114237_bb0310","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/epi.13060","article-title":"Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy","volume":"56","author":"Geffrey","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.expneurol.2022.114237_bb0320","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1042\/bj2790129","article-title":"Molecular cloning of a human cannabinoid receptor which is also expressed in testis","volume":"279","author":"G\u00e9rard","year":"1991","journal-title":"Biochem. J."},{"issue":"43","key":"10.1016\/j.expneurol.2022.114237_bib1004","doi-asserted-by":"crossref","first-page":"16546","DOI":"10.1074\/jbc.RA118.004929","article-title":"Inhibitory effects of cannabidiol on voltage-dependent sodium currents","volume":"293","author":"Ghovanloo","year":"2018","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.expneurol.2022.114237_bb0325","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/sj.bjp.0703599","article-title":"Cannabinoid receptor-mediated inhibition of acetylcholine release from hippocampal and cortical synaptosomes","volume":"131","author":"Gifford","year":"2000","journal-title":"British J. Pharm."},{"issue":"2","key":"10.1016\/j.expneurol.2022.114237_bb0330","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0306-4522(96)00428-9","article-title":"Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal, and adult human brain","volume":"77","author":"Glass","year":"1997","journal-title":"Neurosci."},{"key":"10.1016\/j.expneurol.2022.114237_bb0335","article-title":"Cannabinoids for epilepsy","volume":"3","author":"Gloss","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.expneurol.2022.114237_bb0340","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/978-3-030-57369-0_7","article-title":"Cannabidiol therapy for refractory epilepsy and seizure disorders","volume":"1264","author":"Golub","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.expneurol.2022.114237_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2021.113946","article-title":"Contusion brain injury in mice for modelling of post-traumatic epilepsy with contralateral hippocampus sclerosis: Comprehensive and longitudinal characterization of spontaneous seizures, neuropathology, and neuropsychiatric comorbidities","volume":"348","author":"Golub","year":"2022","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2022.114237_bb0350","series-title":"Epilepsy and other chronic convulsive disorders","author":"Gowers","year":"1881"},{"issue":"4","key":"10.1016\/j.expneurol.2022.114237_bb0355","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.pbb.2011.06.027","article-title":"Effects of intracisternal administration of cannabidiol on the cardiovascular and behavioral responses to acute restraint stress","volume":"99","author":"Granjeiro","year":"2011","journal-title":"Pharmacol. Bicochem. Behav."},{"issue":"S1","key":"10.1016\/j.expneurol.2022.114237_bb0360","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1684\/epd.2020.1135","article-title":"The proposed mechanisms of action of CBD in epilepsy","volume":"22","author":"Gray","year":"2020","journal-title":"Epileptic Disord"},{"issue":"2","key":"10.1016\/j.expneurol.2022.114237_bb0365","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1089\/can.2019.0028","article-title":"Anticonvulsive properties of cannabidiol in a model of generalized seizure are transient receptor potential vanilloid 1 dependent","volume":"5","author":"Gray","year":"2020","journal-title":"Cannabis. Cannabinoid. Res."},{"key":"10.1016\/j.expneurol.2022.114237_bb0370","first-page":"10","article-title":"Cannabinoids and the endocannabinoid system","volume":"1","author":"Grotenhermen","year":"2006","journal-title":"Cannabinoids"},{"issue":"4","key":"10.1016\/j.expneurol.2022.114237_bb0375","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/BF02244012","article-title":"Antianxiety effect of cannabidiol in the elevated plus maze","volume":"100","author":"Guimaraes","year":"1990","journal-title":"Psychopharm."},{"issue":"2","key":"10.1016\/j.expneurol.2022.114237_bb0380","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/ane.13351","article-title":"Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials","volume":"143","author":"Gunning","year":"2021","journal-title":"Acta Neurol. Scand."},{"issue":"14","key":"10.1016\/j.expneurol.2022.114237_bb0385","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1073\/pnas.95.14.8268","article-title":"Cannabidiol and (\u2212)Delta9-tetrahydrocannabidiol are neuroprotective antioxidants","volume":"95","author":"Hampson","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.expneurol.2022.114237_bb0390","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.nbd.2004.08.008","article-title":"Chronic temporal lobe epilepsy is associated with severely declined dentate neurogenesis in the adult hippocampus","volume":"17","author":"Hattiangady","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2022.114237_bb0400","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1111\/epi.13499","article-title":"Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex","volume":"57","author":"Hess","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.expneurol.2022.114237_bb0405","doi-asserted-by":"crossref","first-page":"9406","DOI":"10.1073\/pnas.0914661107","article-title":"Endogenous cannabinoid signaling is essential for stress adaptation","volume":"107","author":"Hill","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.expneurol.2022.114237_bb0410","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1111\/j.1476-5381.2012.02207.x","article-title":"Cannabidivarin is anticonvulsant in mouse and rat","volume":"167","author":"Hill","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2022.114237_bb0415","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/bph.12321","article-title":"Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism","volume":"170","author":"Hill","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2022.114237_bb0420","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.expneurol.2011.11.047","article-title":"Marijuana, endocannabinoids, and epilepsy: potential and challenges for improved therapeutic intervention","volume":"244","author":"Hofmann","year":"2013","journal-title":"Exp. Neurol."},{"issue":"4","key":"10.1016\/j.expneurol.2022.114237_bb0425","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s12031-015-0703-6","article-title":"Cannabidiol post-treatment alleviates rat epileptic-related behaviors and activates hippocampal cell autophagy pathway along with antioxidant defense in chronic phase of pilocarpine-induced seizure","volume":"58","author":"Hosseinzadeh","year":"2016","journal-title":"J. Mol. Neurosci."},{"issue":"3","key":"10.1016\/j.expneurol.2022.114237_bb0430","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0026-895X(25)10219-8","article-title":"Involvement of gi in the inhibition of adenylate cyclase by cannbimimetic drugs","volume":"29","author":"Howlett","year":"1986","journal-title":"Mol. Pharmacol."},{"issue":"8","key":"10.1016\/j.expneurol.2022.114237_bb0435","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1002\/cbdv.200790152","article-title":"Human cannabinoid pharmacokinetics","volume":"4","author":"Huestis","year":"2007","journal-title":"Chem. Biodivers."},{"issue":"9","key":"10.1016\/j.expneurol.2022.114237_bb0440","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1111\/epi.13842","article-title":"Anticonvulsant effect of cannabinoid receptor agonists in models of seizures in developing rats","volume":"58","author":"Huizenga","year":"2017","journal-title":"Epilepsia."},{"key":"10.1016\/j.expneurol.2022.114237_bb0445","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.neuropharm.2019.01.002","article-title":"Preclinical safety and efficacy of cannabidivarin for early life seizures","volume":"148","author":"Huizenga","year":"2019","journal-title":"Neuropharmacology."},{"issue":"2","key":"10.1016\/j.expneurol.2022.114237_bb0450","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0306-4522(00)00120-2","article-title":"Functional expression of cell surface cannabinoid CB1 receptors on presynaptic inhibitory terminals in cultured rat hippocampal neurons","volume":"98","author":"Irving","year":"2000","journal-title":"Neurosci."},{"key":"10.1016\/j.expneurol.2022.114237_bb0455","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2133\/dmpk.DMPK-12-RG-129","article-title":"Cannabidiol is a potent inhibition of the catalytic activity of cytochrome P450 2C19","volume":"28","author":"Jiang","year":"2013","journal-title":"Drug Metab. Pharmacokinetic."},{"key":"10.1016\/j.expneurol.2022.114237_bb0460","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1124\/jpet.109.159145","article-title":"Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo","volume":"332","author":"Jones","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.expneurol.2022.114237_bb0465","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.seizure.2012.03.001","article-title":"Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures","volume":"21","author":"Jones","year":"2012","journal-title":"Seizure."},{"key":"10.1016\/j.expneurol.2022.114237_bb0470","series-title":"Assessment of the anticonvulsant effects and tolerability of GW Pharmaceuticals\u2019 cannabidiol in the anticonvulsant screening program. AES Abstract #3.034","author":"Jones","year":"2015"},{"issue":"13","key":"10.1016\/j.expneurol.2022.114237_bb0475","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1001\/jama.2022.3880","article-title":"Antiseizure medications for adults with epilepsy: a review","volume":"327","author":"Kanner","year":"2022","journal-title":"JAMA"},{"issue":"42","key":"10.1016\/j.expneurol.2022.114237_bb0480","doi-asserted-by":"crossref","first-page":"11229","DOI":"10.1073\/pnas.1711351114","article-title":"Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome","volume":"114","author":"Kaplan","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.expneurol.2022.114237_bb0485","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0306-4522(00)00286-4","article-title":"GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus","volume":"100","author":"Katona","year":"2000","journal-title":"Neurosci."},{"issue":"11","key":"10.1016\/j.expneurol.2022.114237_bb0490","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1523\/JNEUROSCI.4872-05.2006","article-title":"The CB1 cannabinoid receptor is the major cannabinoid receptor at excitatory presynaptic sites in the hippocampus and cerebellum","volume":"26","author":"Kawamura","year":"2006","journal-title":"Neurosci."},{"issue":"7","key":"10.1016\/j.expneurol.2022.114237_bb0495","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1007\/s11064-017-2287-8","article-title":"Evaluation of cannabidiol in animal seizure models by the epilepsy therapy screening program (ETSP)","volume":"42","author":"Klein","year":"2017","journal-title":"Neurochem. Res."},{"issue":"7","key":"10.1016\/j.expneurol.2022.114237_bb0500","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1111\/epi.16071","article-title":"Effects of cannabidiol on brivaracetam plasma levels","volume":"60","author":"Klotz","year":"2019","journal-title":"Epilepsia."},{"issue":"5","key":"10.1016\/j.expneurol.2022.114237_bb0505","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.expneurol.2022.114237_bb0510","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1111\/bph.13250","article-title":"Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor","volume":"172","author":"Laprairie","year":"2015","journal-title":"Br. J. Pharmacol."},{"issue":"17","key":"10.1016\/j.expneurol.2022.114237_bib1010","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s40265-018-0992-5","article-title":"Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis","volume":"78","author":"Lattanzi","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.expneurol.2022.114237_bb0515","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.eplepsyres.2019.03.015","article-title":"Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results","volume":"154","author":"Laux","year":"2019","journal-title":"Epilepsy Res."},{"issue":"10","key":"10.1016\/j.expneurol.2022.114237_bb0520","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1111\/ajt.15398","article-title":"Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus","volume":"19","author":"Leino","year":"2019","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.expneurol.2022.114237_bb0525","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.neuropharm.2015.12.017","article-title":"Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT\/glutamate neurotransmission: role of 5-HT1A receptors","volume":"103","author":"Linge","year":"2016","journal-title":"Neuropharmacology."},{"issue":"1","key":"10.1016\/j.expneurol.2022.114237_bb0530","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euroneuro.2009.08.003","article-title":"Regulation of adult neurogenesis by stress, sleep disruption, exercise and inflammation: Implications for depression and antidepressant action","volume":"20","author":"Lucassen","year":"2010","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.expneurol.2022.114237_bb0535","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/epi.12610","article-title":"The case for medical marijuana in epilepsy","volume":"55","author":"Maa","year":"2014","journal-title":"Epilepsia."},{"issue":"9","key":"10.1016\/j.expneurol.2022.114237_bb0540","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1111\/epi.16974","article-title":"Time to onset of cannabidiol treatment effects in Dravet syndrome: analysis from two randomized controlled trials","volume":"62","author":"Madan Cohen","year":"2021","journal-title":"Epilepsia"},{"issue":"4268","key":"10.1016\/j.expneurol.2022.114237_bb0545","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1126\/science.982057","article-title":"Cannabinoid induced behavioral convulsions in rabbits","volume":"194","author":"Martin","year":"1976","journal-title":"Science."},{"issue":"1","key":"10.1016\/j.expneurol.2022.114237_bb0550","doi-asserted-by":"crossref","first-page":"7778","DOI":"10.1038\/s41598-019-44056-y","article-title":"Synthetic, non-intoxicating 8,9-dihydrocannabidiol for the mitigation of seizures","volume":"9","author":"Mascal","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.expneurol.2022.114237_bb0555","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/BF00450585","article-title":"Toward drugs derived from cannabis","volume":"65","author":"Mechoulam","year":"1978","journal-title":"Naturwissenschaften."},{"issue":"5","key":"10.1016\/j.expneurol.2022.114237_bb0560","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1001\/jamaneurol.2020.0073","article-title":"Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in dravet syndrome: a randomized clinical trial","volume":"77","author":"Miller","year":"2020","journal-title":"JAMA Neurol. 2020"},{"key":"10.1016\/j.expneurol.2022.114237_bb0565","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.nbd.2003.11.010","article-title":"Status epilepticus severity influences the long-term outcome of neurogenesis in the adult dentate gyrus","volume":"15","author":"Mohpael","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2022.114237_bb0570","series-title":"A Phase 1 Investigation Into the Potential Effects of Cannabidiol on CYP3A4-Mediated Drug-Drug Interactions in Healthy Volunteers. AES Abstract # 1.297","author":"Morrison","year":"2018"},{"issue":"8","key":"10.1016\/j.expneurol.2022.114237_bb0575","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/cpdd.665","article-title":"A phase 1, open-label, pharmacokinetic trial to investigate possible drug-drug interactions between clobazam, stiripentol, or valproate and cannabidiol in healthy subjects","volume":"8","author":"Morrison","year":"2019","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.expneurol.2022.114237_bb0580","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/365061a0","article-title":"Molecular characterization of a peripheral receptor for cannabinoids","volume":"365","author":"Munro","year":"1993","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.expneurol.2022.114237_bb0585","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/epi4.12286","article-title":"Epilepsy in tuberous sclerosis complex: Findings from the TOSCA Study","volume":"4","author":"Nabbout","year":"2019","journal-title":"Epilepsia Open"},{"issue":"5","key":"10.1016\/j.expneurol.2022.114237_bb0590","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10459-010-9222-y","article-title":"Likert scales, levels of measurement and the \u201claws\u201d of statistics","volume":"15","author":"Norman","year":"2010","journal-title":"Adv. Health Sci. Educ. Theory Pract"},{"key":"10.1016\/j.expneurol.2022.114237_bb0595","first-page":"253","article-title":"Transdermal cannabidiol (CBD) gel for the treatment of focal epilepsy in adults","volume":"2","author":"O\u2019Brien","year":"2018","journal-title":"AES Abstract"},{"issue":"Pt B","key":"10.1016\/j.expneurol.2022.114237_bb0600","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.yebeh.2016.11.012","article-title":"Cannabinoids in treatment-resistant epilepsy: A review","volume":"70","author":"O'Connell","year":"2017","journal-title":"Epilepsy Behav."},{"issue":"2","key":"10.1016\/j.expneurol.2022.114237_bb0605","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/bms.1200130206","article-title":"Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking ad intravenous administration","volume":"13","author":"Ohlsson","year":"1986","journal-title":"Biomed. Environ. Mass Spectrom."},{"key":"10.1016\/j.expneurol.2022.114237_bib1007","first-page":"2.296","article-title":"Long-term efficacy and tolerability of add-on cannabidiol for drug-resistant pediatric epilepsies","volume":"Dec","author":"Oldham","year":"2015","journal-title":"AES Abstracts"},{"key":"10.1016\/j.expneurol.2022.114237_bb0610","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1523\/JNEUROSCI.17-10-03727.1997","article-title":"Dentate granule cell neurogenesis is increased by seizures and contributes to aberrant network reorganization in the adult rat hippocampus","volume":"17","author":"Parent","year":"1997","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2022.114237_bb0615","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1093\/brain\/aww129","article-title":"Aberrant epilepsy-associated mutant Nav1.6 sodium channel activity can be targeted with cannabidiol","volume":"139","author":"Patel","year":"2016","journal-title":"Brain."},{"key":"10.1016\/j.expneurol.2022.114237_bb0620","series-title":"Long-Term Safety and Efficacy of Add-on Cannabidiol (CBD) Treatment in Patients with Lennox-Gastaut Syndrome (LGS): 3-Year Results of an Open-Label Extension (OLE) Trial (GWPCARE5). AES Abstract #2.436","author":"Patel","year":"2019"},{"issue":"3","key":"10.1016\/j.expneurol.2022.114237_bb0625","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/epi4.12351","article-title":"Cannabidiol reduces seizures following CNS infection with Theiler's murine encephalomyelitis virus","volume":"194","author":"Patel","year":"2019","journal-title":"Epilepsia Open."},{"key":"10.1016\/j.expneurol.2022.114237_bb0630","series-title":"Long-term efficacy and safety of cannabidiol (CBD) in patients with treatment-resistance epilepsies: 4-year results from the expanded access program. International Child Neurology Congress, 2020","author":"Patel","year":"2020"},{"issue":"9","key":"10.1016\/j.expneurol.2022.114237_bb0635","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1111\/epi.17000","article-title":"Long- term safety and efficacy of add- on cannabidiol in patients with Lennox\u2013 Gastaut syndrome: Results of a long- term open- label extension trial","volume":"62","author":"Patel","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.expneurol.2022.114237_bb0640","series-title":"Cannabidiol increases survivability and reduces associated behavioral comorbidities in a mouse model of Dravet syndrome. AES Abstract #1.463","author":"Patra","year":"2018"},{"issue":"2","key":"10.1016\/j.expneurol.2022.114237_bb0645","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/epi.14629","article-title":"Cannabidiol reduces seizures and associated behavioral comorbidities in a range of animal seizure and epilepsy models","volume":"60","author":"Patra","year":"2019","journal-title":"Epilepsia."},{"key":"10.1016\/j.expneurol.2022.114237_bb0650","doi-asserted-by":"crossref","first-page":"6516","DOI":"10.4081\/pr.2016.6516","article-title":"Clobazam and its use in epilepsy","volume":"8","author":"Pernea","year":"2016","journal-title":"Pediatr. Rep."},{"issue":"2","key":"10.1016\/j.expneurol.2022.114237_bb0655","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","article-title":"The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin","volume":"53","author":"Pertwee","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2022.114237_bb0660","series-title":"Handbook of cannabis","first-page":"115","article-title":"Known pharmacological actions of delta-9-tetrahydrocannabinol and of four other chemical constituents of cannabis that activate cannabinoid receptors","author":"Pertwee","year":"2014"},{"issue":"4","key":"10.1016\/j.expneurol.2022.114237_bb0665","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1124\/pr.110.003004","article-title":"International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB\u2081 and CB\u2082","volume":"62","author":"Pertwee","year":"2010","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.expneurol.2022.114237_bb0675","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.yebeh.2013.08.037","article-title":"Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy","volume":"29","author":"Porter","year":"2013","journal-title":"Epilepsy Behav."},{"issue":"5","key":"10.1016\/j.expneurol.2022.114237_bb0680","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1111\/epi.16878","article-title":"Time to onset of cannabidiol (CBD) treatment effects in Lennox Gastaut syndrome: analysis from two randomized controlled trials","volume":"62","author":"Privitera","year":"2021","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.expneurol.2022.114237_bb0685","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1684\/epd.2021.1244","article-title":"Developmental and epileptic encephalopathies: recognition and approaches to care","volume":"23","author":"Raga","year":"2021","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.expneurol.2022.114237_bb0690","doi-asserted-by":"crossref","first-page":"H610","DOI":"10.1152\/ajpheart.00236.2007","article-title":"Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption","volume":"293","author":"Rajesh","year":"2007","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"2","key":"10.1016\/j.expneurol.2022.114237_bb0695","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1586\/ecp.10.3","article-title":"Clinical pharmacokinetic interactions between antiepileptic drugs and hormonal contraceptives","volume":"3","author":"Reddy","year":"2010","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.expneurol.2022.114237_bb0700","first-page":"25","article-title":"Resurgence of cannabinoid phytopharmaceuticals in USA","volume":"48","author":"Reddy","year":"2016","journal-title":"Pharma Times."},{"issue":"2","key":"10.1016\/j.expneurol.2022.114237_bb0705","first-page":"129","article-title":"The utility of cannabidiol in the treatment of refractory epilepsy","volume":"17","author":"Reddy","year":"2017","journal-title":"Clin. Pharmacol. Therap."},{"issue":"6","key":"10.1016\/j.expneurol.2022.114237_bb0710","first-page":"5165","article-title":"Clinical pharmacology and therapeutics of antiepileptic drugs for epilepsy and seizure disorders","volume":"13","author":"Reddy","year":"2020","journal-title":"Int. J. Pharm. Sci. Nanotechnol."},{"key":"10.1016\/j.expneurol.2022.114237_bb0715","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1124\/jpet.115.230151","article-title":"The pharmacological basis of cannabis therapy for epilepsy","volume":"357","author":"Reddy","year":"2016","journal-title":"J. Pharmacol. Exp. Therap."},{"issue":"9","key":"10.1016\/j.expneurol.2022.114237_bb0720","doi-asserted-by":"crossref","first-page":"18284","DOI":"10.3390\/ijms140918284","article-title":"Experimental models of status epilepticus and neuronal injury for evaluation of therapeutic interventions","volume":"14","author":"Reddy","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.expneurol.2022.114237_bb0725","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2021.135753","article-title":"Molecular mechanisms of sex differences in epilepsy and seizure susceptibility in chemical, genetic and acquired epileptogenesis","volume":"750","author":"Reddy","year":"2021","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.expneurol.2022.114237_bb0730","doi-asserted-by":"crossref","DOI":"10.1002\/cpz1.447","article-title":"A comprehensive and advanced mouse model of post-traumatic epilepsy with robust spontaneous recurrent seizures","volume":"2","author":"Reddy","year":"2022","journal-title":"Curr. Protocols."},{"key":"10.1016\/j.expneurol.2022.114237_bb0735","doi-asserted-by":"crossref","first-page":"22647","DOI":"10.1016\/j.expneurol.2022.114240","article-title":"Efficacy of the FDA-approved cannabidiol on the development and persistence of temporal lobe epilepsy and complex focal onset seizures","volume":"359","author":"Reddy","year":"2023","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2022.114237_bb0740","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.bbr.2006.05.016","article-title":"Effects of cannabidiol and diazepam on behavioral and cardiovascular responses induced by contextual conditioned fear in rats","volume":"172","author":"Resstel","year":"2006","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.expneurol.2022.114237_bb0745","series-title":"Epilepsy: its symptoms, treatment, and relation to other chronic convulsive diseases","author":"Reynolds","year":"1861"},{"issue":"Pt A","key":"10.1016\/j.expneurol.2022.114237_bb0750","article-title":"Reduced efficacy and risk of seizure aggravation when cannabidiol is used without clobazam","volume":"103","author":"Rogawski","year":"2020","journal-title":"Epilepsy Behav."},{"issue":"4","key":"10.1016\/j.expneurol.2022.114237_bb0755","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s13311-015-0375-5","article-title":"Cannabinoids and epilepsy","volume":"12","author":"Rosenberg","year":"2015","journal-title":"Neurotherapeutics."},{"issue":"Pt B","key":"10.1016\/j.expneurol.2022.114237_bb0760","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.yebeh.2016.11.006","article-title":"Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection","volume":"70","author":"Rosenberg","year":"2017","journal-title":"Epilepsy Behav."},{"issue":"23","key":"10.1016\/j.expneurol.2022.114237_bb0765","doi-asserted-by":"crossref","first-page":"16124","DOI":"10.1074\/jbc.M707104200","article-title":"Inhibition of recombinant human T-type calcium channels by delta9-tetrahydrocannabinol and cannabidiol","volume":"283","author":"Ross","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.expneurol.2022.114237_bb0770","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1093\/brain\/awv142","article-title":"Dissecting the phenotypes of Dravet syndrome by gene deletion","volume":"138","author":"Rubinstein","year":"2015","journal-title":"Brain."},{"key":"10.1016\/j.expneurol.2022.114237_bb0775","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.58593","article-title":"Cannabidiol interactions with voltage-gated sodium channels","volume":"9","author":"Sait","year":"2020","journal-title":"eLife"},{"key":"10.1016\/j.expneurol.2022.114237_bb0780","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2022.108577","article-title":"A scoping review on cannabidiol therapy in tuberous sclerosis: Current evidence and perspectives for future development","volume":"128","author":"Samanta","year":"2022","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.expneurol.2022.114237_bb0785","series-title":"Long-Term Safety and Efficacy of Add-on Cannabidiol (CBD) Treatment in Patients with Dravet Syndrome (DS) in an Open-Label Extension (OLE) Trial (GWPCARE5). AES Abstract # 1.470","author":"Scheffer","year":"2018"},{"issue":"10","key":"10.1016\/j.expneurol.2022.114237_bb0790","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1111\/epi.17036","article-title":"Add-on cannabidiol in patients with Dravet syndrome: Results of a long-term open-label extension trial","volume":"62","author":"Scheffer","year":"2021","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.expneurol.2022.114237_bb0795","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2165\/00002018-200022060-00005","article-title":"A risk-benefit assessment of therapies for Lennox-Gastaut syndrome","volume":"22","author":"Schmidt","year":"2000","journal-title":"Drug Saf."},{"key":"10.1016\/j.expneurol.2022.114237_bb0800","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.yebeh.2018.07.027","article-title":"Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: a randomized, double-blind, controlled trial","volume":"88","author":"Schoedel","year":"2018","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.expneurol.2022.114237_bb0805","series-title":"Safety and tolerability of ZYN002 (synthetic cannabidiol) transdermal gel in healthy subjects: two phase 1, randomized, double-blind, placebo-controlled studies. Abstract 2.214","author":"Sebree","year":"2016"},{"issue":"14","key":"10.1016\/j.expneurol.2022.114237_bb0810","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.1523\/JNEUROSCI.16-14-04322.1996","article-title":"Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures","volume":"16","author":"Shen","year":"1996","journal-title":"Neurosci."},{"key":"10.1016\/j.expneurol.2022.114237_bib1001","doi-asserted-by":"crossref","first-page":"107966","DOI":"10.1016\/j.neuropharm.2020.107966","article-title":"Mechanisms of action of currently used antiseizure drugs","volume":"168","author":"Sills","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.expneurol.2022.114237_bb0815","first-page":"25","article-title":"Comparative effects between cannabidiol and diazepam on neophobia, food intake, and conflict behavior","volume":"6","author":"Silveira Filho","year":"1981","journal-title":"Res. Commun. Psychol. Psychiatry Behav."},{"issue":"10","key":"10.1016\/j.expneurol.2022.114237_bb0820","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076918","article-title":"Cannabidiol, a non-psychoactive cannabinoid compound, inhibits proliferation and invasion in U87-MG and T98G glioma cells through a multitarget effect","volume":"8","author":"Solinas","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.expneurol.2022.114237_bb0825","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/0024-3205(74)90361-0","article-title":"Delta9-tetrahydrocannabinol: subcortical spike bursts and motor manifestations in a Fischer rat treated orally for 109 days","volume":"14","author":"Stadnicki","year":"1974","journal-title":"Life Sci."},{"key":"10.1016\/j.expneurol.2022.114237_bb0830","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1111\/epi.13889","article-title":"Dravet syndrome and its mimics: beyond SCN1A","volume":"58","author":"Steel","year":"2017","journal-title":"Epilepsia."},{"key":"10.1016\/j.expneurol.2022.114237_bb0835","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.neuron.2016.03.034","article-title":"Cannabinoid type 2 receptors mediate a cell type-specific plasticity in the hippocampus","volume":"90","author":"Stempel","year":"2016","journal-title":"Neuron."},{"key":"10.1016\/j.expneurol.2022.114237_bb0840","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.euroneuro.2015.02.001","article-title":"Delta9-tetrahydrocannabinol alone and combined with cannabidiol mitigate fear memory through reconsolidation disruption","volume":"25","author":"Stern","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"19","key":"10.1016\/j.expneurol.2022.114237_bb0845","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.1111\/bph.15185","article-title":"A systematic review of minor phytocannabinoids with promising neuroprotective potential","volume":"177","author":"Stone","year":"2020","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.expneurol.2022.114237_bb0850","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1124\/mol.118.111864","article-title":"Cannabidiol inhibits endocannabinoid signaling in autaptic hippocampal neurons","volume":"94","author":"Straiker","year":"2018","journal-title":"Mol. Pharmacol."},{"issue":"4","key":"10.1016\/j.expneurol.2022.114237_bb0855","doi-asserted-by":"crossref","first-page":"541","DOI":"10.4300\/JGME-5-4-18","article-title":"Analyzing and interpreting data from likert-type scales","volume":"5","author":"Sullivan","year":"2013","journal-title":"J. Grad. Med. Educ."},{"key":"10.1016\/j.expneurol.2022.114237_bb0860","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.redox.2016.12.029","article-title":"Cannabidiol attenuates OGD\/R-induced damage by enhancing mitochondrial bioenergetics and modulating glucose metabolism via pentose-phosphate pathway in hippocampal neurons","volume":"11","author":"Sun","year":"2017","journal-title":"Redox Biol."},{"issue":"13","key":"10.1016\/j.expneurol.2022.114237_bb0865","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.1073\/pnas.1211204110","article-title":"Cannabinoid- and lysophosphatidylinositol-sensitive receptor GPR55 boosts neurotransmitter release at central synapses","volume":"110","author":"Sylantyev","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"8","key":"10.1016\/j.expneurol.2022.114237_bb0870","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1111\/epi.14477","article-title":"CBD EAP Study Group. Long-Term Safety and Treatment Effects of Cannabidiol in Children and Adults With Treatment-Resistant Epilepsies: Expanded Access Program Results","volume":"59","author":"Szaflarski","year":"2018","journal-title":"Epilepsia."},{"key":"10.1016\/j.expneurol.2022.114237_bb0875","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.yebeh.2018.07.020","article-title":"Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study","volume":"87","author":"Szaflarski","year":"2018","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.expneurol.2022.114237_bb0880","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.yebeh.2019.03.042","article-title":"Higher cannabidiol plasma levels are associated with better seizure response following treatment with a pharmaceutical grade cannabidiol","volume":"95","author":"Szaflarski","year":"2019","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.expneurol.2022.114237_bb0885","doi-asserted-by":"crossref","first-page":"114238","DOI":"10.1016\/j.expneurol.2022.114238","article-title":"Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: a systematic review and meta-analysis","volume":"359","author":"Talwar","year":"2023","journal-title":"Exp. Neurol."},{"issue":"11","key":"10.1016\/j.expneurol.2022.114237_bb0890","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s40263-018-0578-5","article-title":"A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects","volume":"32","author":"Taylor","year":"2018","journal-title":"CNS Drugs."},{"issue":"10125","key":"10.1016\/j.expneurol.2022.114237_bb0895","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","article-title":"GWPCARE4 Study Group. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWCARE4): a randomized, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Thiele","year":"2018","journal-title":"Lancet."},{"key":"10.1016\/j.expneurol.2022.114237_bb0900","series-title":"Effect of Add-On Cannabidiol (CBD) on Seizure Frequency and Seizure-Free Intervals in Patients with Seizures Associated with Tuberous Sclerosis Complex (TSC): Phase 3 Trial GWPCARE6 Post Hoc Analysis. AES Abstract 3.283","author":"Thiele","year":"2021"},{"issue":"3","key":"10.1016\/j.expneurol.2022.114237_bb0905","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/jamaneurol.2020.4607","article-title":"Add-on cannabidiol treatment for drug-resistant seizures in tuberous sclerosis complex: A placebo-controlled randomized clinical trial","volume":"78","author":"Thiele","year":"2021","journal-title":"JAMA Neurol."},{"issue":"2","key":"10.1016\/j.expneurol.2022.114237_bb0910","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/epi.17150","article-title":"Long-term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open-label extension trial","volume":"63","author":"Thiele","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.expneurol.2022.114237_bb0915","series-title":"Double-blind clinical study of cannabidiol as a secondary anticonvulsant, presented at: Marijuana \u201890 International Conference on Cannabis and Cannabinoids; Kolymbari","author":"Trembly","year":"1990"},{"issue":"1","key":"10.1016\/j.expneurol.2022.114237_bib1011","doi-asserted-by":"crossref","first-page":"23462","DOI":"10.1038\/s41598-021-02770-6","article-title":"Efficacy and safety of medical cannabinoids in children: a systematic review and meta-analysis","volume":"11","author":"Treves","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.expneurol.2022.114237_bb0920","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0306-4522(97)00436-3","article-title":"Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system","volume":"83","author":"Tsou","year":"1998","journal-title":"Neuroscience."},{"key":"10.1016\/j.expneurol.2022.114237_bb0925","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.seizure.2016.01.004","article-title":"CBD-enriched medical cannabis for intractable pediatric epilepsy: the current Israeli experience","volume":"35","author":"Tzadok","year":"2016","journal-title":"Seizure."},{"issue":"3","key":"10.1016\/j.expneurol.2022.114237_bb0930","first-page":"e227","article-title":"SUDEP in the North American SUDEP registry: The full spectrum of epilepsies","volume":"93","author":"Verducci","year":"2019","journal-title":"Neurology 2019"},{"key":"10.1016\/j.expneurol.2022.114237_bb0935","first-page":"S0306","article-title":"Prophylactic Administration of Cannabidiol Reduces Microglial Inflammatory Response to Kainate-Induced Seizures and Neurogenesis","volume":"11","author":"Victor","year":"2022","journal-title":"Neuroscience"},{"key":"10.1016\/j.expneurol.2022.114237_bb0940","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0014-2999(01)01243-2","article-title":"Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects","volume":"428","author":"Wallace","year":"2001","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2022.114237_bb0945","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0014-2999(02)02331-2","article-title":"Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity","volume":"452","author":"Wallace","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2022.114237_bb0950","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1124\/jpet.103.051920","article-title":"The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy","volume":"307","author":"Wallace","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.expneurol.2022.114237_bb0955","series-title":"Long-term Efficacy and Safety of Cannabidiol (CBD) in Patients with Tuberous Sclerosis Complex (TSC): 4-year Results from the Expanded Access Program (EAP). Abstract 137. Annual Meeting of the American Epilepsy Society 2020","author":"Weinstock","year":"2020"},{"issue":"06","key":"10.1016\/j.expneurol.2022.114237_bb0960","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1055\/s-0039-1695786","article-title":"Cannabidiol interacts significantly with everolimus\u2014report of a patient with tuberous sclerosis complex","volume":"50","author":"Wiemer-Kruel","year":"2019","journal-title":"Neuropediatrics"},{"issue":"6","key":"10.1016\/j.expneurol.2022.114237_bb0965","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/epi.17237","article-title":"Methodology for classification and definition of epilepsy syndromes with list of syndromes: report of the ILAE Task Force on Nosology and Definitions","volume":"63","author":"Wirrell","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.expneurol.2022.114237_bb0970","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1478-811X-8-12","article-title":"Cannabinoid receptor CB1 mediates baseline and activity-induced survival of new neurons in adult hippocampal neurogenesis","volume":"8","author":"Wolf","year":"2010","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.expneurol.2022.114237_bb0975","series-title":"Time to onset of cannabidiol (CBD) treatment effect and resolution of adverse events (AEs) in the tuberous sclerosis complex (TSC) phase 3 randomized controlled trial (GWPCARE6)(674)","author":"Wu","year":"2020"},{"issue":"5","key":"10.1016\/j.expneurol.2022.114237_bb0980","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/epi.17199","article-title":"Time to onset of cannabidiol treatment effect and resolution of adverse events in tuberous sclerosis complex: post hoc analysis of randomized controlled phase 3 trial GWPCARE6","volume":"63","author":"Wu","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.expneurol.2022.114237_bb0985","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.pharmthera.2017.03.002","article-title":"Epigenetic interventions for epileptogenesis: a new frontier for curing epilepsy","volume":"177","author":"Younus","year":"2017","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.expneurol.2022.114237_bb9099","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/17512433.2018.1386553","article-title":"A resurging boom in new drugs for epilepsy and brain disorders","volume":"11","author":"Younus","year":"2018","journal-title":"Expert Rev Clin Pharmacol."},{"key":"10.1016\/j.expneurol.2022.114237_bb0990","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1476-5381.2009.00521.x","article-title":"Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors","volume":"159","author":"Zanelati","year":"2010","journal-title":"Br. J. Pharmcol."},{"key":"10.1016\/j.expneurol.2022.114237_bb0995","article-title":"Cannabidiol activates neuronal Kv7 channels","volume":"11","author":"Zhang","year":"2022","journal-title":"eLife"},{"key":"10.1016\/j.expneurol.2022.114237_bb1000","first-page":"391","article-title":"Changes in the conditioned emotional response of rats induced by 9-THC, CBD and mixture of the two cannabinoids","volume":"26","author":"Zuardi","year":"1983","journal-title":"Arq. Biol. Tecnol."}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001448862200262X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001448862200262X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T05:55:29Z","timestamp":1762149329000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001448862200262X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":206,"alternative-id":["S001448862200262X"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2022.114237","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic and clinical foundations of cannabidiol therapy for difficult-to-treat seizures in children and adults with refractory epilepsies","name":"articletitle","label":"Article Title"},{"value":"Experimental Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.expneurol.2022.114237","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"114237"}}